The pharmaceutics and delivery of therapeutic polypeptides and proteins

Abstract Proteins and peptides with immunoregulatory properties are a rapidly growing class of pharmacophores for a wide variety of indications in a number of clinical disciplines. Despite the rapid development of these new drugs, they retain severe pharmacologic deficiencies due to their rapid degradation and elimination. This results in their administration at superpharmacological doses and subsequent clinical toxicity. Further, because these compounds often act indirectly, their clinical development path is less obvious than that of other therapeutics. Thus, their development has become focused on a pharmacologic approach predicated on the preclinical identification of therapeutic surrogates and the subsequent testing of a clinical hypothesis. Immunoregulatory peptides and proteins, including cytokines and growth factors, have been used as single agents and in combinations with one another or other therapeutic modalities. Due to the challenge associated with the targeting and delivery of these therapeutics, novel strategies to achieve the desired therapeutic end-points have been developed. This includes the use of peptide inducers or antagonists as well as delivery strategies via gene and cellular therapy. These therapeutic strategies of the future are in response to the pharmacologic deficiencies of proteins and provide exciting new directions for their development in both the near and long term. This review addresses the pharmacologic deficiencies of proteins, preclinical and clinical developmental strategies, and future strategies based on the use of molecular therapeutics. The primary emphasis has been placed on preclinical and clinical studies of immune and hematopoietic augmenting agents. However, we also discuss proteins that are still in animal models, agents whose profile of activity is associated with the induction of a cytokine cascade and the targeted delivery of a gene via hematopoietic stem cells, lymphocytes, or other autologous tissues or tumors.

[1]  T. Blankenstein,et al.  Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. , 1990, Molecular immunology.

[2]  D. Niederwieser,et al.  Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT) , 1987, British journal of haematology.

[3]  T. Back,et al.  Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy. , 1987, Journal of immunology.

[4]  J. Yannelli,et al.  IL-2 and Cellular Therapy:Lymphokine-Activated Killer Cells and Tumor-Derived Activated Cells , 1990 .

[5]  F. Mandelli,et al.  Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. , 1983, Blood.

[6]  H. Deeg,et al.  Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts , 1985 .

[7]  M. O’connell,et al.  Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). , 1987, The New England journal of medicine.

[8]  H. Volk,et al.  Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer , 1991, The Journal of experimental medicine.

[9]  A. Landay,et al.  CHARACTERIZATION OF CIRCULATING SUPPRESSOR T LYMPHOCYTES IN BONE MARROW TRANSPLANT RECIPIENTS , 1987, Transplantation.

[10]  Fierros Le,et al.  The drops of life. I.V. therapy as a nursing responsibility. , 1970 .

[11]  Jaap M Middeldorp,et al.  Recovery of T cell subsets after autologous bone marrow transplantation is mainly due to proliferation of mature T cells in the graft. , 1985, Blood.

[12]  R. Spiegel,et al.  Alfa-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. , 1987, Seminars in oncology.

[13]  Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. , 1990 .

[14]  D. Crowther,et al.  In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. , 1988, British Journal of Cancer.

[15]  A. Hess,et al.  Development of graft-vs.-host disease-like syndrome in cyclosporine- treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity , 1985, The Journal of experimental medicine.

[16]  M. Sznol,et al.  Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. , 1990, Cancer research.

[17]  A. Rimm,et al.  Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity , 1979, Nature.

[18]  S. Rosenberg,et al.  Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Ho,et al.  Clinical implications of increased plasma levels of CD8 in patients with hairy cell leukemia. , 1990, Blood.

[20]  S. Rosenberg,et al.  Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. , 1985, Journal of immunology.

[21]  T. Phillips,et al.  Recombinant leukocyte A interferon in B-cell chronic lymphocytic leukemia: in vivo effects on autologous antitumor immunity. , 1985, Journal of biological response modifiers.

[22]  M. Wadhwa,et al.  In vivo administration of interleukin 2 stimulates mitosis in thymus and bone marrow , 1986, European journal of immunology.

[23]  D. Golde,et al.  Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. , 1988, Annals of internal medicine.

[24]  M. Ratain,et al.  Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b. , 1988, Seminars in oncology.

[25]  J. Apperley,et al.  GENE THERAPY: CURRENT STATUS AND FUTURE DIRECTIONS , 1990, British journal of haematology.

[26]  P. Debré,et al.  Factor requirements activation and proliferation steps of human cd2+cd3−cd4−cd8− early thymocytes , 1989, European journal of immunology.

[27]  K. Orita,et al.  Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases. , 1990, Cancer research.

[28]  T. Sayers,et al.  Antitumor Effects of α-Interferon and γ-Interferon on a Murine Renal Cancer (Renca) in Vitro and in Vivo , 1990 .

[29]  M. Grever,et al.  Treatment of hairy cell leukemia: the Ohio State University experience with deoxycoformycin. , 1987, Leukemia.

[30]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[31]  S. Asano,et al.  ACCELERATION OF NEUTROPHILIC GRANULOCYTE RECOVERY AFTER BONE-MARROW TRANSPLANTATION BY ADMINISTRATION OF RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR , 1988, The Lancet.

[32]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Deeg,et al.  Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. , 1986, Blood.

[34]  R. Herberman,et al.  Rationale for recombinant human interferon-gamma adjuvant immunotherapy for cancer. , 1988, Journal of the National Cancer Institute.

[35]  O. Vos MULTIPLICATION OF HAEMOPOIETIC COLONY FORMING UNITS (CFU) IN MICE AFTER X‐IRRADIATION AND BONE MARROW TRANSPLANTATION , 1972, Cell and tissue kinetics.

[36]  M. Harada,et al.  Administration of human urinary colony stimulating factor after bone marrow transplantation. , 1988, Bone marrow transplantation.

[37]  R. Fisher,et al.  A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Volberding,et al.  Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. , 1984, Annals of internal medicine.

[39]  D. S. Coffey,et al.  Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. , 1987, Cancer research.

[40]  H. Ozer,et al.  B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type I interferon in vitro. , 1986, Blood.

[41]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.

[42]  S. Orkin,et al.  Phenotype of recovering lymphoid cell populations after marrow transplantation , 1985, The Journal of experimental medicine.

[43]  T. Merigan,et al.  Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the american cancer society trial , 1985, Cancer.

[44]  D. Kaplan,et al.  In vivo activity of solid phase interleukin 2. , 1991, Cancer research.

[45]  S. Litwin,et al.  A phase I study of recombinant interleukin 2 plus recombinant beta-interferon. , 1988, Cancer research.

[46]  R. Geller,et al.  Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. , 1989, Blood.

[47]  E. Cronkite,et al.  Post-Radiation Parabiosis and Survival in Rats.∗ , 1951, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[48]  K. Atkinson,et al.  Reconstruction of the haemopoietic and immune systems after marrow transplantation. , 1990, Bone marrow transplantation.

[49]  E. Hersh,et al.  A phase I study of therapy with recombinant granulocyte-macrophage colony-stimulating factor administered by IV bolus or continuous infusion. , 1988, Behring Institute Mitteilungen.

[50]  W. Hryniuk More is better. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  E. Gilboa,et al.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.

[52]  M. Levine,et al.  Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  L. Lum The kinetics of immune reconstitution after human marrow transplantation. , 1987, Blood.

[54]  F. Herrmann,et al.  Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  N. Minato,et al.  IL-7 promotes thymocyte proliferation and maintains immunocompetent thymocytes bearing alpha beta or gamma delta T-cell receptors in vitro: synergism with IL-2. , 1989, Journal of immunology.

[56]  J. Thompson,et al.  Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  M. Socinski,et al.  GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN , 1988, The Lancet.

[58]  A. Huang,et al.  A randomized comparison of two doses of human lymphoblastoid interferon- alpha in hairy cell leukemia. Wellcome HCL Study Group , 1991 .

[59]  M. Ratain,et al.  Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Talmadge Biological response modifiers: realizing their potential in cancer therapeutics , 1986 .

[61]  S. Russell,et al.  Immunity to B16 melanoma in mice immunized with IL‐2‐secreting allogeneic mouse fibroblasts expressing melanoma‐associated antigens , 1992, International journal of cancer.

[62]  T. Tötterman,et al.  Regeneration of functional and activated NK and T sub-subset cells in the marrow and blood after autologous bone marrow transplantation: a prospective phenotypic study with 2/3-color FACS analysis. , 1989, Leukemia.

[63]  R. Miller,et al.  Clonal analysis of T-cell deficiencies in autotransplant recipients. , 1991, Blood.

[64]  G. Keller,et al.  Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors , 1985, Nature.

[65]  S. Perry,et al.  Hemopoietic stem cells in human peripheral blood , 1975, Science.

[66]  A. Mazumder,et al.  Successful therapy of natural killer-resistant pulmonary metastases by the synergism of gamma-interferon with tumor necrosis factor and interleukin-2 in mice. , 1988, Cancer research.

[67]  Eliane Gluckman,et al.  Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. , 1989 .

[68]  T. Boone,et al.  Disulfide and secondary structures of recombinant human granulocyte colony stimulating factor. , 1989, Archives of biochemistry and biophysics.

[69]  A. Asher,et al.  Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. , 1991, Journal of immunology.

[70]  J. Bubeník,et al.  Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. , 1990, Immunology letters.

[71]  W. Paul,et al.  Interleukin 2 induces antigen-reactive T cell lines to secrete BCGF-I , 1983, The Journal of experimental medicine.

[72]  J. Talmadge,et al.  Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. , 1987, Cancer research.

[73]  J. Ajani,et al.  Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. , 1989, Cancer research.

[74]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[75]  H. Tilg,et al.  Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patients. , 1989, Leukemia.

[76]  S. Broder,et al.  Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. , 1990, Blood.

[77]  L. V. van Putten,et al.  Pathologic changes in irradiated monkeys treated with bone marrow. , 1961, Journal of the National Cancer Institute.

[78]  M. Ratain,et al.  Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. , 1990, Blood.

[79]  G. Keller,et al.  Clonal fluctuation within the haematopoietic system of mice reconstituted with retrovirus‐infected stem cells. , 1987, The EMBO journal.

[80]  J. Willson,et al.  Phase II Trial of a Combination of Interferon-βser and Interferon-γ in Patients with Advanced Malignant Melanoma , 1988 .

[81]  A. C. Dubbelman,et al.  A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects. , 1992, British Journal of Cancer.

[82]  J. Goldman,et al.  Transfusion of circulating stem cells. , 1984, Critical reviews in clinical laboratory sciences.

[83]  T. Malinin,et al.  PERIPHERAL LEUKOCYTE INFUSION INTO LETHALLY IRRADIATED GUINEA PIGS. , 1965, Blood.

[84]  R. Vollmer,et al.  Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. , 1989, Journal of the American Academy of Dermatology.

[85]  S. Miyatake,et al.  Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[86]  A. Ghosh,et al.  Lack of correlation between peripheral blood lymphokine‐activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2 , 1989, International journal of cancer.

[87]  J. Gutterman,et al.  Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. , 1988, Cancer research.

[88]  F. Sigaux,et al.  c-myc and c-fos expression during interferon-alpha therapy for hairy cell leukemia. , 1986, Blood.

[89]  K. Eguchi,et al.  Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level , 1988, Japanese journal of cancer research : Gann.

[90]  R. Bast,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. , 1988, The New England journal of medicine.

[91]  M. Baseler,et al.  ANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA , 1988, The Lancet.

[92]  H. Heslop,et al.  Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders , 1990, The Journal of experimental medicine.

[93]  A. Komiyama,et al.  Increases in neutrophil counts by purified human urinary colony-stimulating factor in chronic neutropenia of childhood. , 1988, Blood.

[94]  C. Eaves,et al.  Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures. , 1992, The Journal of clinical investigation.

[95]  Jean E. Sanders,et al.  Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. , 1988, Blood.

[96]  J. Gutterman,et al.  Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration. , 1988, Cancer research.

[97]  David A. Williams,et al.  Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse , 1984, Nature.

[98]  J. Ritz,et al.  Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. , 1992, Blood.

[99]  H. Maguire,et al.  Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. , 1984, Cancer research.

[100]  J. Griffin Hemopoietins in oncology: factoring out myelosuppression. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  T. Whiteside,et al.  Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. , 1989, Blood.

[102]  R. Hoffman,et al.  Recombinant GM-CSF/IL-3 fusion protein: its effect on in vitro human megakaryocytopoiesis. , 1992, Experimental hematology.

[103]  H. Golomb,et al.  Treatment options for hairy-cell leukemia. , 1991, Seminars in oncology.

[104]  J. Gabrilove,et al.  Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. , 1988, The New England journal of medicine.

[105]  W. Farrar,et al.  Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. , 1981, Journal of immunology.

[106]  S. Rosenberg,et al.  Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. , 1985, Journal of immunology.

[107]  D. Olive,et al.  Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. , 1990, Blood.

[108]  K. Eguchi,et al.  Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy. , 1989, Cancer research.

[109]  J. Manning,et al.  Alpha interferon for induction of remission in hairy-cell leukemia. , 1984, The New England journal of medicine.

[110]  M. Moore,et al.  Accelerated recovery of peripheral blood cell counts in mice transplanted with in vitro cytokine-expanded hematopoietic progenitors. , 1992, Experimental hematology.

[111]  M. Toribio,et al.  A role for interleukin 4 in the differentiation of mature T cell receptor gamma/delta + cells from human intrathymic T cell precursors , 1990, The Journal of experimental medicine.

[112]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[113]  E. Tomlinson Impact of the new biologies on the medical and pharmaceutical sciences. , 1992, The Journal of pharmacy and pharmacology.

[114]  D. Reece,et al.  Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]. , 1991, Blood.

[115]  W. McBride,et al.  Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. , 1992, Cancer research.

[116]  A. Waheed,et al.  Demonstration of a blood-bone marrow barrier to macrophage colony-stimulating factor. , 1989, Blood.

[117]  M. Chilosi,et al.  Alpha-interferon activates the natural killer system in patients with hairy cell leukemia , 1986 .

[118]  Ihor R. Lemischka,et al.  Developmental potential and dynamic behavior of hematopoietic stem cells , 1986, Cell.

[119]  S. Piantadosi,et al.  INDUCTION OF GRAFT-VERSUS-HOST DISEASE AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION , 1989, The Lancet.

[120]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[121]  A. Porgador,et al.  Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. , 1992, Cancer research.

[122]  R. Humphries,et al.  Gene transfer to primary normal and malignant human hemopoietic progenitors using recombinant retroviruses. , 1987, Blood.

[123]  H. Müller-Hermelink,et al.  Bone marrow transplantation in rats across strong histocompatibility barriers by selective elimination of lymphoid cells in donor marrow. , 1976, Transplantation proceedings.

[124]  J. Quesada,et al.  Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma. , 1988, Journal of biological response modifiers.

[125]  S. Medendorp,et al.  Phase I Clinical Trial of Interleukin 2 and α-Interferon: Toxicity and Immunologic Effects , 1989 .

[126]  S. Seeber,et al.  A prospective randomized comparison of single‐agent interferon (IFN)‐alpha with the combination of IFN‐alpha and low‐dose IFN‐gamma in chronic myelogenous leukaemia , 1992, European journal of haematology.

[127]  R. Herberman Clinical cancer therapy with IL-2. , 1989, Cancer investigation.

[128]  A. Scarpa,et al.  Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. , 1987, Blood.

[129]  J. Kirkwood,et al.  Interferon alpha in combination with other biologics: the scientific rationale , 1991, British journal of haematology.

[130]  K. Sullivan,et al.  Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. , 1987, Annals of internal medicine.

[131]  J. Dick,et al.  Gene transfer into normal human hematopoietic cells using in vitro and in vivo assays. , 1991, Blood.

[132]  A. Burgess,et al.  Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay. , 1988, Blood.

[133]  A. Kimchi Increased levels of interferon-induced (2'--5') oligo-isoadenylate synthetase in mature T-lymphocytes and in differentiated Friend-erythroleukemic cells. , 1981, Journal of interferon research.

[134]  D. Longo,et al.  Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. , 1985, The American journal of medicine.

[135]  I. Tannock,et al.  A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  R. Elashoff,et al.  Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. , 1986, Annals of internal medicine.

[137]  H. Muss,et al.  Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  L. Kanz,et al.  Combination of cytokines: current status and future prospects , 1991, British journal of haematology.

[139]  H. Klingemann,et al.  Immunotherapy after bone marrow transplantation. , 1991, Bone marrow transplantation.

[140]  R. Freidinger,et al.  Non-peptide ligands for peptide receptors. , 1989, Trends in pharmacological sciences.

[141]  A. Zipursky,et al.  Leukemic reticuloendotheliosis. A failure of monocyte production. , 1976, The New England journal of medicine.

[142]  A. Ganser,et al.  In vitro and in vivo action of recombinant human GM-CSF (rhGM-CSF) in patients with myelodysplastic syndromes. , 1988, Blood cells.

[143]  J. Dick,et al.  Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice , 1985, Cell.

[144]  S. Groshen,et al.  Induction of graft versus leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin 2 therapy. , 1991, Cancer research.

[145]  R. Kurzrock,et al.  Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  J. Quesada,et al.  Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  E. Tomlinson Control of the Biological Dispersion of Therapeutic Proteins , 1990 .

[148]  S. Salmon,et al.  Effects of cloned human leukocyte interferons in the human tumor stem cell assay. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  Chronic B-lymphocytic leukemia cells proliferate and differentiate following exposure to interferon in vitro. , 1986 .

[150]  J. Blay,et al.  Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[151]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[152]  J. Groopman,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. , 1987, The New England journal of medicine.

[153]  H. Micklem,et al.  Limited potential of circulating haemopoietic stem cells , 1975, Nature.

[154]  J. Loutit,et al.  HÆMOPOIETIC STEM CELLS IN THE PERIPHERAL BLOOD , 1967 .

[155]  S. Reed,et al.  Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells , 1989, The Journal of experimental medicine.

[156]  J. Talmadge,et al.  Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. , 1987, Cancer research.

[157]  R. Puri,et al.  Interleukin-2 toxicity. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  B. Aggarwal,et al.  Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon , 1985, Nature.

[159]  R Storb,et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.

[160]  D. Crowther,et al.  Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. , 1989, British Journal of Cancer.

[161]  D. Goeddel,et al.  Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. , 1985, Journal of immunology.

[162]  L. Lum Immune recovery after bone marrow transplantation. , 1990, Hematology/oncology clinics of North America.

[163]  D. Catovsky,et al.  Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocytic leukaemia in transformation. , 1979, British medical journal.

[164]  Jeffrey W. Clark,et al.  Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia , 1988 .

[165]  P. Sideras,et al.  Recombinant interleukin 4/BSF‐1 promotes growth and differentiation of intrathymic T cell precursors from fetal mice in vitro. , 1987, The EMBO journal.

[166]  Z. Maricić,et al.  APPLICATION OF HUMAN LEUCOCYTE INTERFERON IN PATIENTS WITH URINARY BLADDER PAPILLOMATOSIS, BREAST CANCER, AND MELANOMA , 1981, The Lancet.

[167]  J. Reuben,et al.  Treatment of acquired immunodeficiency syndrome--related Kaposi's sarcoma with lymphoblastoid interferon. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  M. Palladino,et al.  Pharmacokinetics of Recombinant Murine Interferon-γ and Human Interferon-αA/D(Bgl) Administered in Concert and Their Influence on Natural Killer Cell Function in Mice , 1988 .

[169]  P. Walther,et al.  Schedule-dependent enhanced lethality with combined administration of actinomycin D and tumor necrosis factor in mice. , 1989, Journal of biological response modifiers.

[170]  T. Nishi,et al.  Mutagenesis of human granulocyte colony stimulating factor. , 1989, Biochemical and biophysical research communications.

[171]  J. Hannigan,et al.  Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[172]  Spiegel Rj The alpha interferons: clinical overview. , 1987 .

[173]  R. Armitage,et al.  Human IL-7: a novel T cell growth factor. , 1989, Journal of immunology.

[174]  H. Deeg,et al.  Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy. , 1982, Transplantation.

[175]  D. Longo,et al.  Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. , 1984, Annals of internal medicine.

[176]  J. Kolitz,et al.  Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2. , 1988, Journal of biological response modifiers.

[177]  I. Fidler,et al.  The biology of tumor metastasis. , 1989, Seminars in oncology.

[178]  R. Schooley,et al.  A randomized placebo-controlled trial of recombinant human interferon alpha 2a in patients with aids , 1988 .

[179]  S. Rosenberg,et al.  Combination Cytokine Immunotherapy with Tumor Necrosis Factor α, Interleukin 2, and α-Interferon and Its Synergistic Antitumor Effects in Mice , 1989 .

[180]  E. Gilboa,et al.  Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. , 1990, Cancer research.

[181]  E. Mihich Future perspectives for biological response modifiers: a viewpoint. , 1986, Seminars in oncology.

[182]  K. Zsebo,et al.  Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium , 1990, Cell.

[183]  W. Boswell,et al.  Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected]. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  S. Rosenberg,et al.  Intraperitoneal administration of interleukin-2 in patients with cancer. , 1986, Archives of surgery.

[185]  J. Villeval,et al.  Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. , 1988, Blood.

[186]  K. Orita,et al.  Antitumor effect of recombinant human interferon-beta and interferon-gamma in combination against human colon cancer cell line in vitro and in nude mice. , 1987, Japanese journal of cancer research : Gann.

[187]  J. Murray,et al.  Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[188]  J. Talmadge,et al.  Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastatic disease , 1988, Journal of cellular biochemistry.

[189]  R. Marcus,et al.  Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. , 1986, Bone marrow transplantation.

[190]  M. Doyle,et al.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli. , 1984, Science.

[191]  R. Barr,et al.  HAEMOPOIETIC ENGRAFTMENT WITH PERIPHERAL BLOOD CELLS IN THE TREATMENT OF MALIGNANT DISEASE , 1982, British journal of haematology.

[192]  E. Frei,et al.  Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy. , 1987, Cancer research.

[193]  R. Hoffmann,et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .

[194]  B. Lanske,et al.  Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses. , 1987, Immunobiology.

[195]  H. Kantarjian,et al.  Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. , 1986, The New England journal of medicine.

[196]  R. Comolli,et al.  Systemic IFN-alpha treatment of multiple bladder papilloma grade I or II patients: pilot study. , 1982, Journal of interferon research.

[197]  T. Mosmann,et al.  IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. , 1991, Journal of immunology.

[198]  E. Kedar,et al.  Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. , 1991, Blood.

[199]  R. Foà,et al.  The inhibitory effect of serum from hairy‐cell leukaemia patients on normal progenitor cells may disappear following prolonged treatment with α‐interferon , 1989 .

[200]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[201]  H. Heslop,et al.  Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. , 1989, Blood.

[202]  R. Coombes,et al.  Effect of human recombinant tumour necrosis factor and rat gamma interferon on nitrosomethylurea-induced mammary tumours. , 1989, British Journal of Cancer.

[203]  M. Toribio,et al.  Involvement of the interleukin 4 pathway in the generation of functional gamma delta T cells from human pro-T cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[204]  Z. Darżynkiewicz,et al.  Effect of recombinant tumor necrosis factor on HL‐60 cells: Cell‐cycle specificity and synergism with actinomycin D , 1987, Journal of cellular physiology.

[205]  M. Socinski,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. , 1988, The New England journal of medicine.

[206]  C. Moertel On lymphokines, cytokines, and breakthroughs. , 1986, JAMA.

[207]  C. Eaves,et al.  High-efficiency gene transfer to human hematopoietic cells maintained in long-term marrow culture. , 1989, Blood.

[208]  R. Abrams,et al.  Cyclophosphamide treatment expands the circulating hematopoietic stem cell pool in dogs. , 1981, The Journal of clinical investigation.

[209]  R Langer,et al.  New methods of drug delivery. , 1990, Science.

[210]  G. Marshall,et al.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.

[211]  R. Dutkowski,et al.  Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon‐gamma , 1988, International journal of cancer.

[212]  O. Gurevitch,et al.  Self-maintenance ability of circulating hemopoietic stem cells. , 1982, Experimental hematology.

[213]  G. Hodgson,et al.  Evidence for stem cells in the peripheral blood of mice. , 1962, Blood.

[214]  Herberman Rb Design of clinical trials with biological response modifiers. , 1985 .

[215]  I. Fehér,et al.  Some properties of the circulating hemopoietic stem cells. , 1974, Blood.

[216]  J. Doroshow,et al.  A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. , 1988, Journal of biological response modifiers.

[217]  C. Boucher,et al.  CLINICAL AND VIROLOGICAL EFFECTS OF HIGH-DOSE RECOMBINANT INTERFERON-α IN DISSEMINATED AIDS-RELATED KAPOSI'S SARCOMA , 1988, The Lancet.

[218]  A. Ganser,et al.  Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study. , 1992, Blood.

[219]  J. P. Lewis,et al.  The repopulating potential and differentiation capacity of hematopoietic stem cells from the blood and bone marrow of normal mice , 1968, Journal of cellular physiology.

[220]  F. Ruscetti,et al.  Administration of recombinant human interleukin-7 alters the frequency and number of myeloid progenitor cells in the bone marrow and spleen of mice. , 1992, Blood.

[221]  S. Mackinnon,et al.  Induction of a syngeneic graft-versus-leukemia effect following bone marrow transplantation for chronic myeloid leukemia. , 1990, Leukemia.

[222]  R. Shadduck,et al.  The effect of recombinant human granulocyte macrophage colony-stimulating factor on neutrophil activation in patients with refractory carcinoma. , 1989, Blood.

[223]  M. Revel The Interferon System in Man: Nature of the Interferon Molecules and Mode of Action , 1984 .

[224]  R. Day,et al.  A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[225]  J. Talmadge,et al.  Screening for Biological Response Modifiers: Methods and Rationale , 1985, Developments in Oncology.

[226]  V. Carreño,et al.  COMBINATION OF RECOMBINANT INTERFERONS ALPHA AND GAMMA IN TREATMENT OF CHRONIC HEPATITIS B , 1987, The Lancet.

[227]  P. Scheurich,et al.  Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. , 1987, Journal of immunology.

[228]  A. Donnenberg,et al.  Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[229]  E. Thomas,et al.  THE RECOVERY OF LETHALLY IRRADIATED DOGS GIVEN INFUSIONS OF AUTOLOGOUS LEUKOCYTES PRESERVED AT -80 C. , 1964, Blood.

[230]  D. Golde,et al.  Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[231]  W. Ludwig,et al.  Modulation of immune functions by long-term treatment with recombinant interferon-alpha 2 in a patient with hairy-cell leukemia. , 1988, Journal of interferon research.

[232]  S. Vedantham,et al.  Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. , 1992, Cancer research.

[233]  J. Ortaldo,et al.  Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon. , 1983, Journal of immunology.

[234]  D. Williams,et al.  Retroviral gene transfer of human adenosine deaminase in murine hematopoietic cells: effect of selectable marker sequences on long-term expression. , 1991, Blood.

[235]  J. Gutterman,et al.  Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor. , 1988, The New England journal of medicine.

[236]  E. Farmer,et al.  Acute Graft-vs-Host Disease: Development Following Autologous and Syngeneic Bone Marrow Transplantation , 1987 .

[237]  K. Foon,et al.  Alpha interferon in the treatment of hematologic malignancies. , 1986, The American journal of medicine.

[238]  E. Holmes,et al.  Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes. , 1988, Cancer research.

[239]  K. Bhalla,et al.  The effect of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) on 3'-azido-3'-deoxythimidine (AZT)-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells , 1989 .

[240]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[241]  P W Mansell,et al.  Pharmacokinetics of recombinant interleukin 2 in humans. , 1990, Cancer research.

[242]  W. Nothdurft,et al.  Studies on the regeneration of the CFU-C population in blood and bone marrow of lethally irradiated dogs after autologous transfusion of cryopreserved mononuclear blood cells. , 2009, Scandinavian journal of haematology.

[243]  S. Agarwal,et al.  Letter: Alpha-fetoprotein in Indian childhood cirrhosis. , 1974, Lancet.

[244]  D. Blaise,et al.  IMPACT OF T-CELL DEPLETION ON OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR STANDARD-RISK LEUKAEMIAS , 1987, The Lancet.

[245]  L. Baldini,et al.  Human recombinant interferon alpha-2C enhances the expression of class II HLA antigens on hairy cells. , 1986, Blood.

[246]  H. Nakauchi,et al.  Synergistic effect of IL-3 and IL-6 on highly enriched murine hemopoietic progenitors. , 1992, Experimental hematology.

[247]  M. Martelli,et al.  Imbalances within the peripheral blood T-helper (CD4+) and T-suppressor (CD8+) cell populations in the reconstitution phase after human bone marrow transplantation. , 1988, Blood.

[248]  J. Johnson,et al.  Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. , 1987, Cancer research.

[249]  W. Franklin,et al.  Is there a direct differentiation‐inducing effect of human recombinant interferon on hairy cell leukemia in vitro? , 1989, Cancer.

[250]  E. Kleinerman,et al.  Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. , 1986, Cancer research.

[251]  K. Cantell,et al.  Preparation of human leukocyte interferon for clinical use. , 1977, Texas reports on biology and medicine.

[252]  Modulation of the expression of major histocompatibility antigens on splenic hairy cells--differential effect upon in vitro treatment with alpha-2b-interferon, gamma-interferon, and interleukin-2. , 1988 .

[253]  G. Pizza,et al.  Tumour regression after intralesional injection of interleukin 2 (IL‐2) in bladder cancer. Preliminary report , 1984, International journal of cancer.

[254]  M. Green,et al.  EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY , 1988, The Lancet.

[255]  A. Fefer,et al.  Very low dose alpha-2b interferon for the treatment of hairy cell leukemia [see comments] , 1989 .

[256]  L. Itri,et al.  Safety and tolerance of recombinant interferon alfa‐2a (roferon®‐A) in Cancer Patients , 1986, Cancer.

[257]  E. Hersh,et al.  Treatment of hairy cell leukemia with alpha interferons , 1986, Cancer.

[258]  R. Cameron,et al.  Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. , 1988, Cancer research.

[259]  Oldham Rk Biologicals and biological response modifiers: fourth modality of cancer treatment. , 1984 .

[260]  K. Tsang,et al.  Induction of interleukin 2 receptor (TAC) by tumor necrosis factor in YT cells. , 1987, Journal of immunology.

[261]  E. Baysal,et al.  An IVS‐I‐117 (G→A) acceptor splice site mutation in the α 1‐globin gene is a nondeletional α‐thalassaemia‐2 determinant in an Indian population , 1993 .

[262]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[263]  P. Bunn,et al.  The role of recombinant interferon alfa‐2a in the therapy of cutaneous t‐cell lymphomas , 1986, Cancer.

[264]  E. Gilboa,et al.  Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[265]  H. Muss Interferon therapy for renal cell carcinoma. , 1987, Seminars in oncology.

[266]  R. Foà,et al.  Effect of alpha-interferon on the immune system of patients with hairy cell leukemia. , 1987, Leukemia.

[267]  P. Fisher,et al.  Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters. , 1989, Anticancer research.

[268]  D. Longo,et al.  The determination of an immunologically active dose of interferon-gamma in patients with melanoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[269]  G. Forni,et al.  Tumor immunotherapy by local injection of interleukin 2 and non-reactive lymphocytes. Experimental and clinical results. , 1988, Progress in experimental tumor research.

[270]  J. Gutterman,et al.  Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. , 1987, The New England journal of medicine.

[271]  R. Bechhofer,et al.  Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. , 1988, Cancer research.

[272]  D. Reece,et al.  Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected] [published erratum appears in Blood 1992 Jun 15;79(12):3397] , 1991 .

[273]  T. Hopp,et al.  Lymphokines: from conjecture to the clinic. , 1986, Seminars in oncology.

[274]  S. Salmon,et al.  Phase I-II Trial of Interferon-α2b by Continuous Subcutaneous Infusion over 28 Days , 1988 .

[275]  A. Huang,et al.  Changes in hairy cells after alpha-interferon treatment as measured by flow cytometry. , 1987, Leukemia.

[276]  R. Hoffman,et al.  Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. , 1992, Blood.

[277]  J. Gutterman,et al.  Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor. , 1988, Blood.

[278]  M. Merino,et al.  Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha. , 1988, Cancer research.

[279]  J. Watson,et al.  Effect of IL-7 on the growth of fetal thymocytes in culture. , 1989, Journal of immunology.

[280]  S. Fosså,et al.  Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. , 1989, European journal of cancer & clinical oncology.

[281]  R. Herberman Interleukin-2 therapy of human cancer: potential benefits versus toxicity. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[282]  David A. Williams,et al.  Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[283]  David A. Williams,et al.  Stem Cell Factor, Interleukin-3, and Interleukin-6 Promote Retroviral-Mediated Gene Transfer Into Murine Hematopoietic Stem Cells , 1992 .